Sample size determination in group-sequential clinical trials with two co-primary endpoints. - Wikidata - awgldk - TriplyDB

Sample size determination in group-sequential clinical trials with two co-primary endpoints.

Sample size determination in group-sequential clinical trials with two co-primary endpoints.

http://www.wikidata.org/entity/Q33848180

about

Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.Sample Size Considerations in Clinical Trials when Comparing Two Interventions using Multiple Co-Primary Binary Relative Risk Contrasts.Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group.Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.Choice of futility boundaries for group sequential designs with two endpoints.Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research.Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

P2860

Q35241669-66E56BCC-2821-4944-AFD7-809A9D54C4A6 Q35836364-89A0B3B8-D6F0-47D8-B78E-16ED88AEDC06 Q36325724-2B019EAB-1C31-4BAF-B3C5-318A87351B32 Q39272947-9D37ECC3-8B4A-4F9F-8718-98B0ACA073F8 Q40090419-4FACA012-E6D6-4D40-9293-2EF083F36E75 Q47189344-E57FEC66-A298-42EC-9643-25EB186D2B47 Q47625359-0882C9F5-8E00-4DFE-9449-59195D2D01FC Q47691559-7399A76A-B952-4A61-A4BA-F892CB5B6881

P2860

Sample size determination in group-sequential clinical trials with two co-primary endpoints.

http://www.wikidata.org/entity/Q33848180

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Sample size determination in g ...... with two co-primary endpoints.

@ast

Sample size determination in g ...... with two co-primary endpoints.

@en

type

label

Sample size determination in g ...... with two co-primary endpoints.

@ast

Sample size determination in g ...... with two co-primary endpoints.

@en

prefLabel

Sample size determination in g ...... with two co-primary endpoints.

@ast

Sample size determination in g ...... with two co-primary endpoints.

@en

P1433

Q33848180-B5212880-6F15-44C1-BC00-8AF7836209B3

P1476

Q33848180-F0709792-B042-41A2-83F0-D069663218F3

P2093

Q33848180-66DF5EC3-4A4D-4846-B433-80F0210ED541

Q33848180-F2157355-27CC-4C44-9DA2-79735A8A6204

Q33848180-F667B93E-0AA2-4730-8F32-38AB4598638B

Q33848180-FB114E57-58A5-47B5-BDA5-C84E89C44501

Q33848180-FCCA191F-C9A7-4159-BBA5-00A550E9668E

P2860

Q33848180-0173265A-094F-4668-A4A7-2548BB21165A

Q33848180-10AC9A3E-0AE5-4A2D-83E9-550353E34AAF

Q33848180-24769CC1-50DA-490C-83C8-A5FC8D09ACCA

Q33848180-2A1B9CC1-6FA1-4E7A-9CDB-5354A230C0B9

Q33848180-2C5516C1-7E7E-4EC1-95EB-C028031CAEB9

Q33848180-39730620-BF47-4D1F-AC10-CA1FC0410CAA

Q33848180-41EBA783-67A0-4DCF-BFEB-71732494DA76

Q33848180-61BB42EE-E68A-4C81-8336-A67F2D1536C5

Q33848180-6467C85C-A50F-4B85-B0B1-29991A1CE057

Q33848180-6A7CFC13-DE82-407B-BEDF-172CE9FAC9DB

P304

Q33848180-A9B720EE-397F-478B-B8D7-F84AD3F39E80

P31

Q33848180-A3049CA8-7CBA-4329-AF8B-5FC933517D2D

P356

Q33848180-C30405BD-9464-4ED6-8F26-8EBE5EB713AE

P407

Q33848180-4F5807DF-6112-45B3-B122-D68E7C587935

P433

Q33848180-E24C1377-CFE8-45CD-B1FA-6966A394DAC0

P478

Q33848180-58FBFD9E-64DE-4F9F-AA68-5DBE1FFCE336

P50

Q33848180-85D2C8EF-C8E1-492F-81F3-B8E554A0B223

P577

Q33848180-63575C29-7941-4E0E-936B-FC722C24A3BE

P698

Q33848180-010EAA18-FB41-473A-9572-C0ACBED31022

P932

Q33848180-6C9FC728-57E0-473A-9D9F-792AE8386785

P356

P1433

Statistics in Medicine

P1476

Sample size determination in g ...... with two co-primary endpoints

@en

P2093

Kenichi Hayashi

http://www.w3.org/2001/XMLSchema#string

Koko Asakura

http://www.w3.org/2001/XMLSchema#string

Scott R Evans

http://www.w3.org/2001/XMLSchema#string

Takashi Sozu

http://www.w3.org/2001/XMLSchema#string

Tomoyuki Sugimoto

http://www.w3.org/2001/XMLSchema#string

P2860

A multiple testing procedure for clinical trials

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

Testing a primary and a secondary endpoint in a group sequential design.

The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.

A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.

Sample size determination for clinical trials with co-primary outcomes: exponential event times.

Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial.

Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.

Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints.

Sample sizes for trials involving multiple correlated must-win comparisons.

P304

2897-2913

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/SIM.6154

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Toshimitsu Hamasaki

P577

2014-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24676799

http://www.w3.org/2001/XMLSchema#string

P932

4082481

http://www.w3.org/2001/XMLSchema#string